http://square.umin.ac.jp/seedbook


|   ホーム   |   腎臓病   |   電解質異常   |   高血圧   |   研究   |   論文集   |  

 論文集


論文

    1. Tanemoto M. Necessity of adjusting the blood hemoglobin target owing to interdialytic weight gain in patients on maintenance hemodialysis. Hemodial Int. 2023 Jun 26. doi: 10.1111/hdi.13108. Epub ahead of print. PMID: 37364993.
    2. Tanemoto M. Vasopressin V2 receptor antagonists for the syndrome of inappropriate antidiuretic hormone secretion. Int Urol Nephrol. 2023 May 23. doi: 10.1007/s11255-023-03643-9. Epub ahead of print. PMID: 37219713
    3. Tanemoto M, Kasai T, Iida Y. Linagliptin possibly enhances the efficacy of allosteric xanthine oxidase inhibitors. Int Urol Nephrol. 2023 May 8. doi: 10.1007/s11255-023-03625-x. Epub ahead of print. PMID: 37155141
    4. Iida Y, Tanemoto M, Kasai T, Inoshita S. Solubility of crystals in acetone: a diagnostic tool for crystalluria. Int Urol Nephrol. 2023 Apr 30. doi: 10.1007/s11255-023-03614-0. Epub ahead of print. PMID: 37120787
    5. Tanemoto M. Key questions regarding the SYMPLICITY HTN-3 trial. Lancet. 2023 Apr 22;401(10385):1337. doi: 10.1016/S0140-6736(23)00336-7. PMID: 37087165
    6. Tanemoto M, Kasai T, Iida Y. Possible parathyroid calcium-sensing set point shift in patients undergoing maintenance hemodialysis. Ther Apher Dial. 2023 Mar 10. doi: 10.1111/1744-9987.13982. Epub ahead of print. PMID: 36897216
    7. Tanemoto M. Adjustment of anion gap for other serum components is of little benefit to acid-base assessment. Clin Exp Nephrol. 2023 Apr;27(4):392-393. doi: 10.1007/s10157-022-02311-z. Epub ahead of print. PMID: 36645585
    8. Tanemoto M. Vaptans for hyponatraemia. Br J Clin Pharmacol. 2023 Feb;89(2): 921. doi: 10.1111/bcp.15593. Epub ahead of print. PMID: 36424365
    9. Tanemoto M. Standardization of acid-base assessment. A nephrology picture. J Nephrol. 2022 Jun 23. doi: 10.1007/s40620-022-01387-w. Epub ahead of print. PMID: 35737290.
    10. Tanemoto M, Kimura T. Hypocalciuric Hypercalcemia Due to Isolated Renal Granulomatous Disease. Am J Med. 2022 Jul;135(7):e207-e208. doi: 10.1016/j.amjmed.2022.02.013. Epub 2022 Mar 12. PMID: 35292286
    11. Tanemoto M, Suenaga S. Hyponatremia reflects mortality risks other than myocardial damage in acute coronary syndrome. Intern Emerg Med. 2022 Jun; 17(4):590-591. doi: 10.1007/s11739-021-02915-5.
    12. Tanemoto M, Kimura T, Yamada S. Daily dose of alfacalcidol at conversion from intravenous maxacalcitol in secondary hyperparathyroidism management. Ther Apher Dial. 2022; Apr; 26: 471-472. Nov 4. doi: 10.1111/1744-9987.13751.
    13. Tanemoto M. Identifying individual-specific baseline anion gap is of little benefit to acid-base assessment. Intern Emerg Med. 2022 Mar;17(2):575-576. doi: 10.1007/s11739-021-02826-5. Epub ahead of print. PMID: 3438993
    14. Tanemoto M, Kimura T, Yamada S. Necessity of examining the practical efficacy of phosphate binders. Clin Exp Nephrol. 2021 Oct 30. doi: 10.1007/s10157-021-02155-z. Epub ahead of print. PMID: 34716828.
    15. Tanemoto M, Katsuoka Y. Conversion from intravenous maxacalcitol to oral vitamin D in secondary hyperparathyroidism management. Clin Exp Nephrol. 2022 Jan;26(1):97-98.
    16. Tanemoto M. Identifying individual-specific baseline anion gap is of little benefit to acid-base assessment. Intern Emerg Med. 2021 Aug 13. doi: 10.1007/s11739-021-02826-5. Epub ahead of print. PMID: 34389934.
    17. Tanemoto M. Lessons for the clinical nephrologist: a midsummer night's cluster of hypernatremia cases. J Nephrol. 2021 Apr 15. doi: 10.1007/s40620-021-01047-5. Epub ahead of print. PMID: 33856684.
    18. Kimura T, Yokoyama T, Yamada S, Tanemoto M. Salvation of peritoneal dialysis catheter potency by using an angiographic guidewire. Perit Dial Int. 40(6):603-605, 2020
    19. Kimura T, Yokoyama T, Tanemoto M. Renal tubular injury by glyphosate-based herbicide. Clin Exp Nephrol. 24(12):1186, 2020
    20. Tanemoto M, Kamachi R, Kimura T, Yamada S, Yokoyama T, Okazaki Y. Hyperchloremic acidosis develops at the stage G4 and shifts to high anion gap acidosis at the stage G5 in chronic kidney disease. Clin Exp Nephrol. 24(12):1140-1143, 2020
    21. Tanemoto M. Progression of Metabolic Acidosis in Chronic Kidney Disease. Kidney Dis (Basel). 6(1):59-63, 2020
    22. Tanemoto M, Tsubata H, Oouchi H, Okazaki Y. Potential over-the-limit correction of serum sodium concentration owing to device performance. Intern Emerg Med. 15(6):1113-1115, 2020
    23. Tanemoto M. Healthy Dietary Patterns But Not Fruit and Vegetables Keep Mortality Away: A Caution for Trials of Fruit and Vegetables in Dialysis Patients. Ther Apher Dial. 24(2):236-237,2020
    24. Tanemoto M. Renal angioplasty deteriorated the outcome of shockwave therapy for atherosclerotic renal artery stenosis. J Hypertens. 37(11):2301-2302, 2019
    25. Tanemoto M. Diagnosis of unilateral aldosterone hypersecretion in adrenal venous sampling. J Hypertens. 37(10):2110, 2019
    26. Tanemoto M, Kimura T, Yamada S, Yokoyama T, Okazaki Y. Difference in Bicarbonate Calculation Algorithm by Manufacturer Alters Diagnosis of Acid-Base Disorders. Ann Biomed Eng. 47(12):2351-2352,2019
    27. Tanemoto M. Gap acidosis except lactic acidosis develops and progresses during chronic kidney disease stage G5. Clin Exp Nephrol. 23: 1045-1049, 2019
    28. Tanemoto M. Diagnosis of unilateral aldosterone hypersecretion in adrenal venous sampling. J Hypertens. 37: 2110, 2019
    29. Tanemoto M. Possible causes of plasma aldosterone reduction in primary aldosteronism. J Hypertens. 37:1529, 2019
    30. Tanemoto M, Tomita T, Motoharu Y, Urata M, Okazaki Y. Influence of Hemofiltration on Intradialytic Plasma Volume Decrease. Kidney Blood Press Res. 44: 88-93, 2019
    31. Tanemoto M. Influence on renal blood flow in renal denervation procedures. J Hypertens. 37: 453-454, 2019
    32. Tanemoto M. Instrument errors of an analyzer influence acid-base assessment. Clin Exp Nephrol. 23: 719-720, 2019
    33. Tanemoto M, Ishimoto Y, Kosako Y, Okazaki Y. Comparison of intradialytic plasma volume change between online hemodiafiltration and standard hemodialysis Renal Replacement Therapy 4: 42, 2018
    34. Tanemoto M. Diagnostic Use of Base Excess in Acid-Base Disorders. N Engl J Med. 379: 495, 2018
    35. Tanemoto M. The analysis of hemoglobin A1c in dialysis patients should include the variables
      that reflect the erythrocyte turnover. Kidney Int. 94: 220-221, 2018
    36. Tanemoto M. Calculated Bicarbonate for Acid-Base Disorders. Am J Med. 130: 1135-1136, 2017
    37. Tanemoto M. Lateralization of renal blood flow and renin secretion in
      fibromuscular dysplasia. J Hypertens. 35:1720-1721, 2017
    38. Tanemoto M. Renal resistive index for resistant hypertension. J Hypertens. 35:1525-1526, 2017
    39. Tanemoto M. Biomarkers for right-sided heart failure. Hypertens Res. 40: 899, 2017
    40. Tanemoto M. Arterial stiffening by blood pressure increase. J Hypertens. 35: 1326, 2017
    41. Tanemoto M. Iron restriction in renovascular hypertension. Hypertens Res. 40: 627, 2017
    42. Tanemoto M, Ishimoto Y, Saito H. Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series. Blood Purif. 43: 97-100, 2017
    43. Tanemoto M. High-sensitive C-reactive protein in primary aldosteronism. J Hypertens. 35: 200-201, 2017
    44. Tanemoto M. Blood pressure reduction after renal denervation in obese hypertensive swine model. J Hypertens. 35: 199. 2017
    45. Tanemoto M, Okazaki Y. Restenosis of renal artery fibromuscular dysplasia after percutaneous angioplasty. J Hypertens. 34: 2298,2016
    46. Tanemoto M, Saitoh H, Ishimoto Y. AT1-pathway inhibition in aneurysm growth and cardiac failure. J Hypertens. ;34: 1654, 2016
    47. Higaki M, Tanemoto M, Shiraishi T, Taniguchi K, Fujigaki Y, Uchida S. Acute Kidney Injury Facilitates Hypocalcemia by Exacerbating the Hyperphosphatemic Effect of Muscle Damage in Rhabdomyolysis. Nephron. 131: 11-6, 2015
    48. Kato H, Shiraishi T, Ueda S, Kubo E, Shima T, Nagura M, Yano H, Izumikawa Y, Shimada M, Tomioka S, Nosaka H, Kojima K, Tanemoto M, Uchida S. Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology. Clin Exp Nephrol. 19: 465-73, 2015
    49. Tanemoto M, Abe T, Uchida S, Kawahara K, Mislocalization of K+ channels causes the renal salt wasting in EAST/SeSAME syndrome. FEBS letters. 588: 899-905, 2014
    50. Yano H, Tamura Y, Kobayashi K, Tanemoto M, Uchida S. Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease. Clinical and Experimental Nephrology. 18:50-55, 2014
    51. Souma T, Abe M, Moriguchi T, Takai J, Yanagisawa-Miyazawa N, Shibata E, Akiyama Y, Toyohara T, Suzuki T, Tanemoto M, Abe T, Sato H, Yamamoto M, Ito S. Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells. Journal of American Society of Nephrology. 22: 635-648, 2011
    52. 内田俊也，鵜沼智、冨丘聡、熊谷天哲、田村好古、兒島憲一郎，種本雅之、本間桂子、小山雄平、柴田洋孝. 偽性アルドステロン症の発現を予知するグリチルリチン負荷試験の考案．臨床体液 38: 91-94, 2011
    53. Toyohara T, Suzuki T, Akiyama Y, Yoshihara D, Takeuchi Y, Mishima E, Kikuchi K, Suzuki C, Tanemoto M, Ito S, Nagao S, Soga T, Abe T. Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model. Clinical and Experimental Nephrology. 15: 676-687, 2011
    54. Tanemoto M, Uchida S. Angiotensin II induced phosphorylation of the sodium chloride cotransporter. Kidney International. 79: 1381, 2011
    55. Toyohara T, Akiyama Y, Suzuki T, Takeuchi Y, Mishima E, Tanemoto M, Momose A, Toki N, Sato H, Nakayama M, Hozawa A, Tsuji I, Ito S, Soga T, Abe T. Metabolomic profiling of uremic solutes in CKD patients. Hypertension Research. 33: 944-952, 2010
    56. Abe M, Toyohara T, Ishii A, Suzuki T, Noguchi N, Akiyama Y, Shiwaku H O, Nakagomi-Hagihara R, Zheng G, Shibata E, Souma T, Shindo T, Shima H, Takeuchi Y, Mishima E, Tanemoto M, Terasaki T, Onogawa T, Unno M, Ito S, Takasawa S, Abe T. The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides. Drug Metabolism and Pharmacokinetics. 25: 274-282, 2010
    57. Tanemoto M, Takeuchi Y, Mishima E, Suzuki T, Abe T, Ito S. Stages of chronic kidney disease is an outcome-predicting factor for atheromatous renal artery steosis. Hypertension Research 33: 1206-1210, 2010
    58. Miyazawa N, Abe M, Soma T, Tanemoto M, Abe T, Nakayama M, Ito S. Methylglyoxal auguments intracellular oxidative stress in human aortic endothelial cells. Free Radical Research. 44: 101-107, 2010
    59. Tanemoto M. The cause of metabolic acidosis. Kidney International. 78: 110, 2010
    60. Tanemoto M, Suzuki T. Abe M, Abe T, Ito S. Hemodynamic Index of Atheromatous Renal Artery Stenosis for Angioplasty. Clinical Journal of American Society of Nephrology. 4: 651-655, 2009
    61. Tanemoto M, Suzuki T. Abe M, Abe T, Ito S. Physiologic variance of corticotrophin affects diagnosis in adrenal vein sampling. European Journal of Endocrinology. 160: 459-463, 2009
    62. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku OH, Takeuchi Y, Mishima E, Abe M, Tanemoto M, Masuda S, Kawano H, Maemura K, Nakayama M, Sato H, Mikkaichi T, Yamaguchi H. Fukui S, Fukumoto Y, Shimokawa H, Inui K, Terasaki T, Goto J, Ito S, Hishinuma T, Rubera I, Tauc M, Fujii-Kuriyama Y, Yabuuchi H, Moriyama Y, Soga T, Abe T. SLCO4C1 transporter eliminates uremic toxins preventing hypertension and renal inflammation. Journal of American Society of Nephrology. 20: 2546-2555, 2009
    63. Tanemoto M, Takeuchi Y, Mishima E, Abe T, Ito S. Possible cause of recurrent renal artery stenosis. Kidney International. 76: 1209, 2009
    64. Tanemoto M. Limited significance of iodomethylnorcholesterol uptake in adrenal visualization. Kidney International. 76: 678, 2009
    65. Tanemoto M, Mishima E, Takeuchi Y, Abe T. Adrenocorticotropic Hormone Stimulation during Adrenal Vein Sampling. Hypertension. 54: e23, 2009
    66. Tanemoto M. Causative vascular abnormalities for the renal ischemia. Kidney International. 75: 1354, 2009
    67. Tanemoto M. Treatment for hyperkalemia in hyporeninemic hypoaldosteronism. Kidney International. 75: 1113, 2009
    68. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, Ishidoya S, Arai Y, Takahashi K, Sasano H, Ito S. Immunohistochemistry of a proliferation Marker Ki67/MIB1 in Adrenocortical Carcinomas: Ki67/MIB1 Labeling Index is a Predictor for Recurrence of Adrenocortical Carcinomas. Endocrine Journal. 55: 49-55, 2008
    69. Tanemoto M, Toyohara T, Abe T, Ito S. MAGI-1a functions as a scaffolding protein for the distal renal tubular basolateral K+ channels. Journal of Biological Chemistry.  283: 12241-12247, 2008
    70. Tanemoto M, Abe M, Uruno A, Abe T, Ito S. Angiographic index for angioplasty-treatable atheromatous renal artery stenosis. Hypertension Research.  31: 881-885, 2008
    71. Nishi H, Inagi R, Hideki Kato, Tanemoto M, Kojima I, Son D, Fujita T, and Nangaku M. Hemoglobin Is Expressed by Mesangial Cells and Reduces Oxidant Stress. Journal of American Society of Nephrology. 19: 1500-1508, 2008
    72. Tanemoto M, Effect of serum albumin on serum sodium: necessity to consider the Donnan effect. QJM-An International Journal of Medicine. 101: 827-828, 2008
    73. Tanemoto M, Abe T, Ito S. Diagnosis of aldosterone producing adenomas. Kidney International. 73: 362-363, 2008
    74. Tanemoto M, Abe T, Ito S. Treatment of fibromuscular dysplasia. Kidney International. 74: 244, 2008
    75. Satoh F, Abe T, Tanemoto M, Nakamura M, Abe M, Uruno A, Morimoto R, Sato A, Takase K, Ishidoya S, Arai Y, Suzuki T, Sasano H, Ishibashi T, Ito S. Localization of Aldosterone-Producing Adrenocortical Adenomas: Significance of Adrenal Venous Sampling. Hypertension Research. 30: 1083-1095, 2007
    76. Tanemoto M, Abe M, Satoh F, Abe T, Ito S. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not ? - Round 2. Journal of Hypertension. 25: 1517-1518, 2007
    77. Tanemoto M, Abe M, Satoh F, Abe T, Ito S. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not ? Journal of Hypertension. 25: 480-481, 2007
    78. Tanemoto M, Abe T, Ito S. PDZ-binding and di-hydrophobic motifs regulate distribution of Kir4.1 channels in renal cells. Journal of American Society of Nephrology. 16: 2608-2614, 2005
    79. Tanemoto M, Saitoh H, Satoh F, Satoh H, Abe T, Ito S. Predictors of Undiagnosed Renal Artery Stenosis among Japanese Patients with Risk Factors of Atherosclerosis. Hypertension Research. 28: 237-242, 2005
    80. Tanemoto M, Abe T, Onogawa T, Ito S. PDZ binding motif dependent localization of K+ channel on basolateral-side in distal tubules. American Journal of Physiolology-Renal Physiolology. 287: F1148-F1153, 2004
    81. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui KI, Ito S, Goto J, Abe T. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceeding of National Academy of Science U S A. 101: 3569-3574, 2004
    82. Adachi H, Suzuki T, Abe M, Aasano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T. Molecular characterization of human and rat organic anion transporter OATP-D. American Journal of Physiolology-Renal Physiolology. 285: F1188-F1197, 2003
    83. Suzuki T, Onogawa T, Asano N, Mizutamari H, Mikkaichi T, Tanemoto M, Abe M, Satoh F, Unno M, Nunoki K, Suzuki M, Hishinuma T, Goto J, Shimosegawa T, Matsuno S, Ito S, Abe T. Identification and characterization of novel rat and human gonad specific organic anion transporters. Molecular Endocrinology. 17: 1203-1215, 2003
    84. Sato K, Sugawara J, Sato T, Mizutamari H, Suzuki T, Ito A, Mikkaichi T, Onogawa T, Tanemoto M, Unno M, Abe T, Okamura K. Expression of Organic Anion Transporting Polypeptide E (OATP-E) in Human Placenta. Placenta. 24: 144-148, 2003
    85. Tanemoto M, Fujita A, Higashi K, Kurachi Y. PSD-95 mediates formation of a functional homomeric Kir5.1 channel in the brain. Neuron. 34: 387-397, 2002
    86. Lourdel S, Paulais M, Cluzeaud F, Bens M, Tanemoto M, Kurachi Y, Vandewalle A, Teulon J. An inward rectifier K(+) channel at the basolateral membrane of the mouse distal convoluted tubule: similarities with Kir4-Kir5.1 heteromeric channels. Journal of Physiolology-London. 538: 391-404, 2002
    87. Higashi K, Fujita A, Inanobe A, Tanemoto M, Doi K, Kubo T, Kurachi Y. An inwardly rectifying K(+) channel, Kir4.1, expressed in astrocytes surrounds synapses and blood vessels in brain. American Journal of Physiolology-Cell Physiolology. 281: C922-C931, 2001
    88. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 120: 1689-1699, 2001
    89. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology.  142: 2005-2012, 2001
    90. Kusaka S, Inanobe A, Fujita A, Makino Y, Tanemoto M, Matsushita K, Tano Y, Kurachi Y. Functional Kir7.1 channels localized at the root of apical processes in rat retinal pigment epithelium. Journal of Physiolology-London. 531: 27-36, 2001
    91. Tanemoto M, Kittaka N, Inanobe A, Kurachi Y. In vivo formation of a proton-sensitive K+ channel by heteromeric subunit assembly of Kir5.1 with Kir4.1. Journal of Physiolology-London.  525: 587-592, 2000
    92. Hibino H, Inanobe A, Tanemoto M, Fujita A, Doi K, Kubo T, Hata Y, Takai Y, Kurachi Y. Anchoring proteins confer G protein sensitivity to an inward-rectifier K(+) channel through the GK domain. EMBO Journal. 19: 78-83, 2000
    93. Matsuoka T, Matsushita K, Katayama Y, Fujita A, Inageda K, Tanemoto M, Inanobe A, Yamashita S, Matsuzawa Y, Kurachi Y. C-terminal tails of sulfonylurea receptors control ADP-induced activation and diazoxide modulation of ATP-sensitive K(+) channels. Circulation Research. 87: 873-880, 2000
    94. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T. Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochemical and Biophysical Research Communications. 275: 831-838, 2000
    95. Tanemoto M, Vanoye CG, Dong K, Welch R, Abe T, Hebert SC, Xu JZ. Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte. American Journal of Physiolology-Renal Physiolology. 278: F659-F666, 2000
    96. Inanobe A, Horio Y, Fujita A, Tanemoto M, Hibino H, Inageda K, Kurachi Y. Molecular cloning and characterization of a novel splicing variant of the Kir3.2 subunit predominantly expressed in mouse testis. Journal of Physiolology-London. 521: 19-30, 1999
    97. Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, Yawo H. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. Journal of Biological Chemistry. 273: 22395-22401, 1998
    98. Jackman JK, Motto DG, Sun Q, Tanemoto M, Turck CW, Peltz GA, Koretzky GA, Findell PR. Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells. Journal of Biological Chemistry. 270: 7029-7032, 1995

症例報告

    1. Tanemoto M, Kimura T. Hypocalciuric Hypercalcemia Due to Isolated Renal Granulomatous Disease. Am J Med. 2022 Mar 12:S0002-9343(22)00174-7. doi: 10.1016/j.amjmed.2022.02.013. Epub ahead of print. PMID: 35292286
    2. Tanemoto M, Kimura T. Possible influence of atheroembolism in anticoagulant-related nephropathy: a nephrology image. J Nephrol. 2022 Feb 28. doi: 10.1007/s40620-022-01280-6. Epub ahead of print. PMID: 3522630
    3. Kimura T, Yamada S. Tanemoto M, Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report. SN Comprehensive Clinical Medicine 2022;4:34
    4. Kimura T, Suzuki M, Yokoyama T, Kanetsuna Y, Tanemoto M. Lessons for the clinical nephrologist: acute kidney injury by a glyphosate-surfactant herbicide. J Nephrol. 2021 Feb 8. doi: 10.1007/s40620-021-00975-6. Epub ahead of print. PMID: 33555576.
    5. Kimura T, Yokoyama T, Tanemoto M. Complicated peritoneal dialysis-associated peritonitis caused by Brevibacterium. Ther Apher Dial. 2021 Oct;25(5):717-718.
    6. Yokoyama T, Suzuki M, Kimura T, Tanemoto M. Bilateral lipomatous neoplasia surrounding the kidneys. Kidney Int. 99(3):775, 2021
    7. Kimura T, Yokoyama T, Tanemoto M. Renal tubular injury by glyphosate-based herbicide. Clin Exp Nephrol. 24(12):1186, 2020
    8. Tanemoto M, Yamada S, Kimura T, Yokoyama T, Okazaki Y. Misdiagnosis of high anion gap acidosis owing to instrument error of a device. CEN Case Rep. 8(4):308-310, 2019
    9. Tanemoto M, Higaki M, Amano K, Toyoki D, Arai S, Tomioka S, Uchida S. Sonographic detection of a radiolucent object in dialysis vascular access. Journal of Clinical Ultrasound. 43:397-399, 2015
    10. Kato H, Fujigaki Y, Inoue R, Asakawa S, Shin S, Shima T, Furunishi J, Higaki M, Tanemoto M, Yamaguchi Y, Hoshimoto K, Uozaki H, Uchida S. Therapeutic dose of acetaminophen as a possible risk factor for acute kidney injury: learning from two healthy young adult cases. Internal Medicine. 53:1531-1534, 2014
    11. Asakawa S, Tanemoto M, Kawamorita Y, Okura R, Fujigaki Y, Uchida S. Lack of Blood Flow in Bilateral Renal Cortex. JSM Clin Case Rep 2: 1054, 2014
    12. Tanemoto M, Takeuchi Y, Mishima E, Suzuki T, Abe T, Ito S. Urinary stones resembling uric acid stones. Nephrology Dialysis and Transplantation Plus. 3: 318-319, 2010
    13. Tanemoto M, Uruno A, Abe T, Ito S. Hypocalcemia in a patient with severe hypertension and surgically induced relative hypoparathyroidism. Journal of Bone and Mineral Metabolism. 26: 298-300, 2008
    14. 豊原敬文、種本雅之、宇留野晃、阿部倫明、阿部高明、伊藤貞嘉．常用量の漢方薬内服中に横紋筋融解症を呈した一例．日本腎臓学会誌 50: 135-139, 2008
    15. Tanemoto M, Takase K, Abe T, Satoh F, Ishibashi T, Ito S. Dilation of renal artery stenosis after administration of losartan. Hypertension Research. 30: 999-1002, 2007
    16. Tanemoto M, Abe M, Uruno A, Satoh F, Abe T, Ito S. Mesangial proliferative glomerulonephritis with aldosterone producing adenoma. Clinical and Experimental Nephrology. 11: 164-167, 2007
    17. Tanemoto M, Honkura K, Abe M, Satoh F, Abe T, Ito S. Aldosterone producing adenoma accompanied with renal artery stenosis. Journal of Nephrology. 19: 540-542, 2006
    18. Tanemoto M, Abe T, Chaki T, Ishibashi T, Satoh F, Ito S. Cutting balloon angioplasty of resistant renal artery stenosis caused by fibromuscular dysplasia. Journal of Vascular Surgery. 41: 898-901, 2005
    19. Tanemoto M, Abe T, Satoh F, Ito S. Bilateral calcified renal artery aneurysms in a patient with von Recklinghausen’s disease. Nephrology Dialysis and Transplantation. 20: 1007-1008, 2005
    20. Tanemoto M, Abe T, Satoh F, Ito S. Plasma renin activity revealed renal artery stenosis concealed by aneurysms. Urology. 65: 592.e29-529e31, 2005
    21. Tanemoto M, Abe M, Satoh F, Abe T, Ito S. Renal Artery Dissection after Angiographic Evaluation of Lower Extremities. Hypertension Research. 28: 853-855, 2005
    22. Tanemoto M, Ito S. Reply for Regarding "Cutting balloon angioplasty of renal fibromuscular dysplasia: a word of caution". Journal of Vascular Surgery. 42: 1039-1040, 2005
    23. 種本雅之、阿部高明、茶木辰治、鈴木恵綾、阿部倫明、佐藤文俊、伊藤貞嘉.　重症高血圧におけるアンジオテンシンII受容体拮抗薬と アンジオテンシン変換酵素阻害薬の併用経験—症例報告を中心として−. Therapeutic Research 25: 1883-1889, 2004
    24. Tanemoto M, Abe T, Obara N, Abe M, Satoh F, Ito S. Successful treatment of severe hypertension with combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research. 26: 863-868, 2003
    25. Tanemoto M, Miyakawa H, Hanai J, Yago M, Kitaoka M, Uchida S. Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. American Journal of Kidney Diseases. 26: 774-780, 1995


総説

    1. Tanemoto M. Diagnosis and therapy of atheromatous renal artery stenosis. Clinical and Experimental Nephrology. 17: 765-770, 2013
    2. 種本雅之．腎遠位尿細管K+イオン輸送の制御機構．腎と透析 74: 287-292, 2013
    3. 種本雅之、内田俊也．Fluid and electrolytes． 日本腎臓学会誌 54: 26-30, 2012
    4. 種本雅之．尿細管輸送におけるシグナル伝達　K輸送．腎と透析 67: 345-349, 2009
    5. 種本雅之．腎病理と腎生理から慢性腎臓病を考える．診断と治療 96: 1565-1571, 2008
    6. 種本雅之．生体のイオンバランスを制御する分子機構の解明．東北医誌 119: 67-69, 2007
    7. Tanemoto M. Regulatory mechanism of “K+-recycling” for Na+-reabsorption in renal tubules. Clinical and Experimental Nephrology. 11: 1-6, 2007
    8. 種本雅之．海外におけるCKDの疫学研究．内科  100: 19-24, 2007
    9. 種本雅之．ナトリウム摂食・排泄のバランス調節機構．東北医誌 118: 47-50, 2006
    10. 種本雅之、茶木辰治、佐藤文俊、阿部高明、伊藤貞嘉．循環血漿量を制御する分子機構の解明．血圧 13: 271-274, 2005
    11. 種本雅之、阿部高明、伊藤貞嘉．大動脈炎症候群による高血圧．内科診療Q & A 699: 56-59, 2003
    12. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The Organic Anion Transporter (OATP) Family. Drug Metabolism and Pharmacokinetics. 19: 171-179, 2004,
    13. 三日市剛、鈴木健弘、種本雅之、後藤順一、伊藤貞嘉、阿部高明．輸送基質からみた有機アニオントランスポーターOATPファミリーの 役割．臨床薬理 35: 51-59, 2004
    14. 種本雅之．Liddle症候群とBartter症候群．現代医療 31: 121-126, 1999
    15. 種本雅之、内田俊也．Bartter症候群の病態生理．medicina 31: 1960-1962, 1994
    16. 種本雅之、内田俊也．血尿と蛋白尿．毎日ライフ 9: 35-37, 1994
    17. 種本雅之、内田俊也．透析骨症の分類と病態．臨床透析 10: 547-555, 1994
    18. 種本雅之、内田俊也、黒川　清．加齢に伴う水・電解質代謝．腎と透析 35: 869-873, 1993
    19. 竹田　秀、種本雅之、内田俊也．輸液剤の種類．臨床と薬物治療 12: 31-35, 1993


著書

    1. 種本雅之：９．腎疾患　腎血管性高血圧症　（総編集　山口徹、北原光夫、福井次矢）　今日の治療指針2013　557-558　医学 書院　2013、分担執筆
    2. 種本雅之：９．腎疾患　代謝性アルカローシス　（監修　山口徹、北原光夫）　今日の治療指針2014　557-558　医学書院　 2013、分担執筆
    3. 種本雅之；腎臓　D. 水電解質異常　１．低Na+血症のメカニズムと臨床的な意義　（編集　富野康日己、柏原直樹、成田一衛）　Annual Review 2013　 290-298　中外医学社 2012、分担執筆
    4. 種本雅之：11．水・電解質異常の病態と治療の実際　（編著　南学正臣）　臨床腎臓病マニュアル　219-240　南光堂　 2012、分担執筆
    5. 種本雅之：第２章　各論　CKD　利尿薬（トルバプタンを含めて）（編集　小林正貴、南学正臣、吉村吾志夫）　腎疾患治療のエビデン ス　第２版　115-117　文光堂　2012、分担執筆
    6. 種本雅之、内田俊也：腎血管系障害　腎動脈線維筋性異形成　腎臓症候群（第２版）　283-286　日本臨床社　2010、分担執筆
    7. 種本雅之：Chapter 5　包括的な診療の提案　４．RAS阻害薬以外の降圧薬の使い方　慢性腎臓病CKD　病態理解に基づいた予防と治療のあり方 （監修　伊藤貞嘉、柏原直樹）　195-203　メディカルレビュー社 2009、分担執筆
    8. 種本雅之：CKDの治療各論　腎動脈狭窄症／腎血管性高血圧／虚血性腎症　CKDのすべて　384-389　腎と透析Vol.67増 刊号 2009、分担執筆
    9. 種本雅之、伊藤貞嘉：4章　主要な腎疾患　D.血管に病変の主座がある場合　2. 一次性の血管系疾患と二次性の血管疾患　5．腎梗塞，コレステロール塞栓，腎静脈血栓症　（編集　今井裕一、安田隆、力石辰也）　 腎尿路系　コア・カリキュラムテスト　254-257文光堂 2008、分担執筆
    10. 種本雅之、伊藤貞嘉：本態性高血圧？　Hypertension フォーカス 2008、分担執筆
    11. 伊藤貞嘉、種本雅之：腎臓　3章　腎硬化症 Q2 どのような時に良性腎硬化症を疑うのか？診断のポイントは？編集　富野康日己、柏原直樹　専門医のための薬物療法Q&A　216-218、中外医 学社 2007、分担執筆
    12. 種本雅之：腎臓　3章　腎硬化症 Q3良性腎硬化症の基本的治療方針は何か？高血圧合併時の降圧目標と適した降圧薬は何か？（編集　富野康日己、柏原直樹）　専門医のための薬物療法 Q&A　219-221、中外医学社 2007、分担執筆
    13. 種本雅之、伊藤貞嘉：第２章Q28 どんな症状が出たら輸液処方を変更しますか？編集　飯野靖彦　水・電解質がわかる輸液ケアQ&A 60-61、中山書店 2006、分担執筆
    14. 種本雅之、伊藤貞嘉：第２章Q29 輸液による危険な症状は何故出るのですか？編集　飯野靖彦　水・電解質がわかる輸液ケアQ&A 62-63、中山書店 2006、分担執筆
    15. Tanemoto M, Fujita A, Kurachi Y：Inwardly-Rectifying K(+) Channels in the Heart. In: Edited by: Nicholas Sperelakis, Yoshihisa Kurachi, Andre Terzic and Michael Cohen. Heart Physiol and Pathophysiol. 4th ed. Philadelphia, Elsevier Inc. 281-307, 2001
    16. 種本雅之、内田俊也：動脈血CO2分圧/動脈血O2分圧、オキシメーター/血漿HCO3-濃度/動脈血pH/Base excess(BE) 　臨床検査のABC　日本医師会雑誌：194-206、1994、分担執筆
    17. 高野哲司、種本雅之：ポリアミン/5-HIAA(5-hydroxyindole acetic acid)　臨床検査のABC　日本医師会雑誌：67-68、1994、分担執筆







タネホン　 Seed Book
http://square.umin.ac.jp/seedbook